Cargando…
Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
Background and Aims: Non-invasive fibrosis staging is essential in metabolic associated fatty liver disease (MAFLD). Transient elastography (TE) is a well-established method for liver fibrosis assessment. We have previously shown that the macrophage marker sCD163 is an independent predictor for fibr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775526/ https://www.ncbi.nlm.nih.gov/pubmed/33392234 http://dx.doi.org/10.3389/fmed.2020.616212 |
_version_ | 1783630487072276480 |
---|---|
author | Kazankov, Konstantin Rosso, Chiara Younes, Ramy Armandi, Angelo Hagström, Hannes Møller, Holger Jon Stål, Per Bugianesi, Elisabetta Grønbæk, Henning |
author_facet | Kazankov, Konstantin Rosso, Chiara Younes, Ramy Armandi, Angelo Hagström, Hannes Møller, Holger Jon Stål, Per Bugianesi, Elisabetta Grønbæk, Henning |
author_sort | Kazankov, Konstantin |
collection | PubMed |
description | Background and Aims: Non-invasive fibrosis staging is essential in metabolic associated fatty liver disease (MAFLD). Transient elastography (TE) is a well-established method for liver fibrosis assessment. We have previously shown that the macrophage marker sCD163 is an independent predictor for fibrosis in MAFLD. In the present study we tested whether the combination of macrophage markers and TE improves fibrosis prediction. Methods: We measured macrophage markers soluble (s)CD163 and mannose receptor (sMR) in two independent cohorts from Italy (n = 141) and Sweden (n = 70) with biopsy-proven MAFLD and available TE. Results: In the Italian cohort, TE and sCD163 showed similar moderate associations with liver fibrosis (rho = 0.56, p < 0.001 and rho = 0.42, p < 0.001, respectively). TE had an area under the Receiver Operating Characteristics curve (AUROC, with 95% CI) for fibrosis; F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.81 (0.73–0.89), F4 = 0.95 (0.90–1.0). sCD163 also predicted fibrosis well [F ≥ 2 = 0.71 (0.63–0.80), F ≥ 3 = 0.82 (0.74–0.90), F4 = 0.89 (0.76–1.0)]. However, combining sCD163 and TE did not improve the AUROCs significantly [F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.85 (0.78–0.92), F4 = 0.97 (0.93–1.0)]. In the Swedish cohort, TE showed a closer association with fibrosis (rho = 0.73, p < 0.001) than sCD163 (rho = 0.43, p < 0.001) and sMR (rho = 0.46, p < 0.001). TE predicted fibrosis well [F ≥ 2 = 0.88 (0.80–0.97), F ≥ 3 = 0.90 (0.83–0.97), F4 = 0.87 (0.78–0.96)], whereas sCD163 did not (best AUROC 0.75). sMR showed a better prediction [F ≥ 2 = 0.68 (0.56–0.81), F ≥ 3 = 0.82 (0.71–0.92), F4 = 0.79 (0.66–0.93)], but the addition of sMR did not further improve the prediction of fibrosis by TE. Conclusion: In these cohorts of MAFLD patients, TE was superior to macrophage markers for fibrosis prediction and in contrast to our hypothesis the addition of these markers to TE did not improve its predictive capability. |
format | Online Article Text |
id | pubmed-7775526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77755262021-01-02 Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease Kazankov, Konstantin Rosso, Chiara Younes, Ramy Armandi, Angelo Hagström, Hannes Møller, Holger Jon Stål, Per Bugianesi, Elisabetta Grønbæk, Henning Front Med (Lausanne) Medicine Background and Aims: Non-invasive fibrosis staging is essential in metabolic associated fatty liver disease (MAFLD). Transient elastography (TE) is a well-established method for liver fibrosis assessment. We have previously shown that the macrophage marker sCD163 is an independent predictor for fibrosis in MAFLD. In the present study we tested whether the combination of macrophage markers and TE improves fibrosis prediction. Methods: We measured macrophage markers soluble (s)CD163 and mannose receptor (sMR) in two independent cohorts from Italy (n = 141) and Sweden (n = 70) with biopsy-proven MAFLD and available TE. Results: In the Italian cohort, TE and sCD163 showed similar moderate associations with liver fibrosis (rho = 0.56, p < 0.001 and rho = 0.42, p < 0.001, respectively). TE had an area under the Receiver Operating Characteristics curve (AUROC, with 95% CI) for fibrosis; F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.81 (0.73–0.89), F4 = 0.95 (0.90–1.0). sCD163 also predicted fibrosis well [F ≥ 2 = 0.71 (0.63–0.80), F ≥ 3 = 0.82 (0.74–0.90), F4 = 0.89 (0.76–1.0)]. However, combining sCD163 and TE did not improve the AUROCs significantly [F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.85 (0.78–0.92), F4 = 0.97 (0.93–1.0)]. In the Swedish cohort, TE showed a closer association with fibrosis (rho = 0.73, p < 0.001) than sCD163 (rho = 0.43, p < 0.001) and sMR (rho = 0.46, p < 0.001). TE predicted fibrosis well [F ≥ 2 = 0.88 (0.80–0.97), F ≥ 3 = 0.90 (0.83–0.97), F4 = 0.87 (0.78–0.96)], whereas sCD163 did not (best AUROC 0.75). sMR showed a better prediction [F ≥ 2 = 0.68 (0.56–0.81), F ≥ 3 = 0.82 (0.71–0.92), F4 = 0.79 (0.66–0.93)], but the addition of sMR did not further improve the prediction of fibrosis by TE. Conclusion: In these cohorts of MAFLD patients, TE was superior to macrophage markers for fibrosis prediction and in contrast to our hypothesis the addition of these markers to TE did not improve its predictive capability. Frontiers Media S.A. 2020-12-18 /pmc/articles/PMC7775526/ /pubmed/33392234 http://dx.doi.org/10.3389/fmed.2020.616212 Text en Copyright © 2020 Kazankov, Rosso, Younes, Armandi, Hagström, Møller, Stål, Bugianesi and Grønbæk. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Kazankov, Konstantin Rosso, Chiara Younes, Ramy Armandi, Angelo Hagström, Hannes Møller, Holger Jon Stål, Per Bugianesi, Elisabetta Grønbæk, Henning Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease |
title | Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease |
title_full | Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease |
title_fullStr | Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease |
title_full_unstemmed | Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease |
title_short | Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease |
title_sort | macrophage markers do not add to the prediction of liver fibrosis by transient elastography in patients with metabolic associated fatty liver disease |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775526/ https://www.ncbi.nlm.nih.gov/pubmed/33392234 http://dx.doi.org/10.3389/fmed.2020.616212 |
work_keys_str_mv | AT kazankovkonstantin macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT rossochiara macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT younesramy macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT armandiangelo macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT hagstromhannes macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT møllerholgerjon macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT stalper macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT bugianesielisabetta macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease AT grønbækhenning macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease |